ParamountNYSE: PGRE

Paramount Global (PARAA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Paramount Global-B (PARA) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Designed by Ariat in collaboration with Yellowstone costume designer Johnetta Boone, fans can see the stunning limited-edition collection in the hit Paramount Network show's new season and shop the looks through both Ariat and Amazon. Designed by Ariat in collaboration with Yellowstone costume designer Johnetta Boone, fans can see the stunning limited-edition collection in the hit Paramount Network show's new season and shop the looks through both Ariat and Amazon.

Paramount Group, Inc. (NYSE:PGRE ) Q3 2024 Earnings Call October 31, 2024 10:00 AM ET Company Participants Tom Hennessy - Vice President, Business Development and Investor Relations Albert Behler - Chairman, Chief Executive Officer and President Wilbur Paes - Chief Operating Officer, Chief Financial Officer and Treasurer Peter Brindley - Executive Vice President and Head, Real Estate Conference Call Participants Blaine Heck - Wells Fargo Stephen Sakwa - Evercore ISI Dylan Burzinski - Green Street Operator Good day, ladies and gentlemen. Thank you for standing by.

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

NEW YORK , Oct. 8, 2024 /PRNewswire/ -- Paramount Global (NASDAQ: PARA, PARAA) announced today that it will report third quarter financial results on Friday, November 8, 2024. The company will conduct a conference call at 8:30 a.m.

If you are looking for stocks that have gained strong momentum recently but are still trading at reasonable prices, Paramount Global (PARAA) could be a great choice. It is one of the several stocks that passed through our 'Fast-Paced Momentum at a Bargain' screen.

Cardiff Oncology's Onvansertib shows promise in treating RAS-mutated metastatic colorectal cancer, potentially opening a massive market with an estimated $567 million to $3.78 billion in annual US sales. Onvansertib has demonstrated superior efficacy and safety over historical controls and competitors, particularly in bevacizumab-naïve patients, with impressive objective response rates and progression-free survival. Positive data from the ongoing CRDF-004 trial could lead to significant upside for Cardiff, attracting potential partnerships or acquisition interest from big pharma, including Pfizer.

WINNEMUCCA, Nev., Oct. 04, 2024 (GLOBE NEWSWIRE) -- Paramount Gold Nevada Corp. (NYSE American: PZG) (“Paramount” or the “Company”) is pleased to announce that during a state Technical Review Team (“TRT”) meeting on October 3rd, the Environmental Evaluation (“EE”) for the Grassy Mountain project was approved as completed. The approval marks the start of the 225-day legislated timeline for the issuance of draft permits.